BerGenBio ASA: Share capital increase

Bergen, Norway, 14 December 2017 – Reference is made to the stock exchange notice published by BerGenBio ASA (the "Company") (OSE: BGBIO) on 17 November 2017 where the Company announced that the board of directors of the Company had resolved to increase the Company's share capital in connection with the exercise options pursuant to the Company's employee share option program. A total of 165,000 options were exercised at an average subscription price of NOK 9.73 per share. The share capital increase has been duly registered in the Norwegian Register of Business Enterprises. Following such registration, the Company’s share capital is NOK 4,992,220 divided into 49,922,200 shares, each with a nominal value of NOK 0.10.

-End-

Contacts  

Richard Godfrey

CEO, BerGenBio ASA

+47 917 86 304

Tom Henrik Sundby

Finance Director, BerGenBio ASA

tom.sundby@bergenbio.com

+47 477 54 415

Forward looking statements

This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

About Us

BerGenBio is a clinical-stage biopharmaceutical company focused on developing a pipeline of first-in-class selective AXL kinase inhibitors to treat multiple aggressive cancers. The Company is a world leader in understanding the central role of AXL kinase in promoting cancer spread, immune evasion and drug resistance – the cause of approximately 90 percent of cancer deaths. Inhibition of AXL kinase activity represents a novel approach to addressing a key mechanism in the evolution of cancer cell malignancy and aggressiveness, offering an opportunity to create important new therapeutic options for cancer patients.

Subscribe

Documents & Links